FDA To Revise Warning Label On Bone Drugs

Law360, New York (October 13, 2010, 5:08 PM EDT) -- The U.S. Food and Drug Administration is revising the label on bisphosphonate-based osteoporosis drugs to warn consumers that they could raise the risk of a rare type of thigh-bone fracture.

While it is not clear whether the drugs are the cause, atypical femur fractures have been predominantly reported in patients taking bisphosphonates to treat osteoporosis, the FDA said Wednesday.

The FDA also plans to require drug companies to include a medication guide with the drugs informing patients of the possible increased fracture risk.

Bisphosphonates are at...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

DUKE et al v. MERCK & CO., INC.


Case Number

3:09-cv-05693

Court

New Jersey

Nature of Suit

Personal Inj. Prod. Liability

Judge

Joel A. Pisano

Date Filed

November 9, 2009

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.